Gufic Biosciences Limited (NSE:GUFICBIO)

Market Cap	38.12B
Revenue (ttm)	8.10B
Net Income (ttm)	819.76M
Shares Out	n/a
EPS (ttm)	8.17
PE Ratio	46.50
Forward PE	n/a
Dividend	0.10 (0.03%)
Ex-Dividend Date	Sep 17, 2024

Volume	45,832
Average Volume	62,041
Open	376.90
Previous Close	374.25
Day's Range	374.85 - 384.55
52-Week Range	278.00 - 504.25
Beta	0.52
RSI	58.56
Earnings Date	May 29, 2025

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 1,491
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GUFICBIO

Financial Performance

In 2023, Gufic Biosciences's revenue was 8.07 billion, an increase of 16.80% compared to the previous year's 6.91 billion. Earnings were 861.36 million, an increase of 8.07%.